All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
While Amgen Inc. recorded an 18 percent increase in revenues for 2005, the company's stock slid Thursday when it failed to release much-anticipated data for its colorectal cancer drug panitumumab. (BioWorld Today)
